plerixafor has been researched along with Bone Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, J; Guo, Y; Hao, D; Huang, Y; Jiang, K; Li, J; Shan, L; Wang, B; Wang, L; Yang, T; Zhang, J; Zhang, Q | 1 |
| Chen, Y; Ma, J; Qi, Z; Xi, Y | 1 |
| Barwick, B; Boise, L; Chen, HR; Chen, J; Dong, JT; Fu, C; Kowalski, J; Kucuk, O; Li, M; Li, X; Li, Y; Osunkoya, AO; Qian, WP; Vertino, PM; Wu, D; Wu, Q; Xia, S; Xie, L; Yang, L; Zhang, B; Zhao, Y; Zhou, W | 1 |
| Fan, L; Gao, QM; Li, GD; Liao, YX; Liu, KY; Lv, JY; Xu, TY; Yang, D; Yu, HY; Zhou, ZF | 1 |
| Chen, LP; Cui, WQ; Hu, XM; Shen, W; Xu, H; Yang, W; Zhang, H; Zhang, HL | 1 |
| Dong, L; Dong, MQ; Fan, QY; Long, H; Ma, BA; Yan, K; Yang, TT; Zhang, P; Zhou, Y | 1 |
| Biordi, L; Di Cesare, E; Festuccia, C; Gravina, GL; Jannini, EA; Mancini, A; Mattei, C; Muzi, P; Pompili, S; Ricevuto, E; Ventura, L | 1 |
| Cher, ML; Chinni, SR; Conley-LaComb, MK; Heath, EI; Kim, S; Li, Y; Semaan, L; Singareddy, R | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Lanza, F; Lemoli, R; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Ananias, HJ; de Jong, IJ; De Vries, EG; Domanska, UM; Huls, G; Kliphuis, NM; Kruizinga, RC; Nagengast, WB; Oude Munnink, TH; Timmer-Bosscha, H; Walenkamp, AM | 1 |
| Apicelli, A; Eagleton, MC; Hirbe, AC; Morgan, EA; Piwnica-Worms, D; Prior, JL; Trinkaus, K; Uluçkan, O; Weilbaecher, K | 1 |
11 other study(ies) available for plerixafor and Bone Neoplasms
| Article | Year |
|---|---|
SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Benzylamines; Bone Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Female; Heterocyclic Compounds; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Osteosarcoma; Programmed Cell Death 1 Receptor; Receptors, CXCR4; Tumor Microenvironment | 2019 |
PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.
Topics: Animals; Benzylamines; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Cyclams; Down-Regulation; Gene Knockdown Techniques; Heterocyclic Compounds; Humans; Lung; Lung Neoplasms; Male; Mice; Osteosarcoma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclams; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Interleukin-11; Kruppel-Like Transcription Factors; Male; Mice; Mutation; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Signal Transduction; Transforming Growth Factor beta | 2021 |
CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
Topics: Animals; Autophagic Cell Death; Benzylamines; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Doxorubicin; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2021 |
Chemokine receptor CXCR4 regulates CaMKII/CREB pathway in spinal neurons that underlies cancer-induced bone pain.
Topics: Animals; Benzylamines; Bone Neoplasms; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cancer Pain; Carcinogenesis; Chemokine CXCL12; Cyclams; Cyclic AMP Response Element-Binding Protein; Estrenes; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Injections, Spinal; Membrane Glycoproteins; Neuroglia; Neurons; Pyrrolidinones; Rats; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Spinal Cord | 2017 |
CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF.
Topics: Animals; Benzylamines; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Culture Media, Conditioned; Cyclams; Heterocyclic Compounds; Heterografts; Humans; Lung Neoplasms; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Osteosarcoma; Receptors, CXCR4; Vascular Endothelial Growth Factor A | 2013 |
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Benzylamines; Blotting, Western; Bone Neoplasms; Cell Adhesion; Cell Movement; Chemokine CXCL12; Coculture Techniques; Cyclams; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds; Heterografts; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Nude; Peptides; Prostatic Neoplasms; Receptors, CXCR4; Tomography, X-Ray Computed; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2015 |
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Topics: Animals; Benzylamines; Bone Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Models, Animal; ErbB Receptors; GTP-Binding Protein alpha Subunits, Gi-Go; Heterocyclic Compounds; Humans; Male; Membrane Microdomains; Mice; Phosphorylation; Prostatic Neoplasms; Receptor, ErbB-2; Receptors, CXCR4; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Blood Component Removal; Bone Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclams; Europe; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Male; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Sarcoma, Ewing; Stem Cell Transplantation; Wiskott-Aldrich Syndrome; Young Adult | 2012 |
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Taxoids; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner.
Topics: Animals; Anti-HIV Agents; Benzylamines; Bone Density; Bone Neoplasms; Bone Resorption; Cell Movement; Cyclams; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neutropenia; Neutrophils; Osteoclasts; Receptors, CXCR4; Tumor Burden | 2007 |